9 Osteogenesis Imperfecta Clinical Trials in Chapel Hill, NC (2026)

Q: How do I join a clinical trial in Chapel Hill?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Chapel Hill research site will contact you.

Recruiting Osteogenesis Imperfecta Studies in Chapel Hill

NCT03511118Recruiting

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently t...

Chapel Hill, NC1,600 participantsDuke University

View Study Details

NCT06008795Recruiting

BLOCK-SAH - PPF-Block for Post-SAH Headache

BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of bilateral pterygopalatine fossa (PPF) injecti...

Chapel Hill, NC195 participantsUniversity of Florida

View Study Details

NCT04588922Recruiting

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies

SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation grou...

Chapel Hill, NC160 participantsSellas Life Sciences Group

View Study Details

NCT07223203Recruiting

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, a...

Chapel Hill, NC125 participantsAlnylam Pharmaceuticals

View Study Details

NCT05401097Recruiting

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

This phase II study compares the order of treatment with ivosidenib or enasidenib and azacitidine plus venetoclax in treating older patients with acute myeloid leukemia with genetic changes in the IDH...

Chapel Hill, NC125 participantsAlice Mims

View Study Details

NCT05442216Recruiting

Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

A treatment cycle is 28 days for Cycle 1 and Cycle 2. Tagraxofusp will be administered at 12 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 5 consecutive days (or 5 doses over a period not to...

Chapel Hill, NC53 participantsJoshua Zeidner

View Study Details

NCT06533098Recruiting

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT)....

Chapel Hill, NC50 participantsJanssen Research & Development, LLC

View Study Details

NCT06222580Recruiting

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

This phase I trial tests the safety, side effects, and best dose of SNDX-5613 and gilteritinib for treating patients with acute myeloid leukemia that has come back after a period of improvement (relap...

Chapel Hill, NC30 participantsUma Borate

View Study Details

NCT06902376Recruiting

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid can...

Chapel Hill, NC12 participantsUNC Lineberger Comprehensive Cancer Center

View Study Details

About Osteogenesis Imperfecta Clinical Trials in Chapel Hill

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 9 osteogenesis imperfecta clinical trials recruiting participants in Chapel Hill, NC. These studies are seeking a combined 2,350 participants. Research is being sponsored by Duke University, University of Florida, Sellas Life Sciences Group and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Chapel Hill — FAQ

Are there osteogenesis imperfecta clinical trials in Chapel Hill?

Yes, there are 9 osteogenesis imperfecta clinical trials currently recruiting in Chapel Hill, NC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chapel Hill?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chapel Hill research site will contact you about next steps.

Are clinical trials in Chapel Hill free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chapel Hill studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 9 active trials in Chapel Hill are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated July 13, 2026 from ClinicalTrials.gov